英文名称 | Lenacapavir (Synonyms: GS-6207) |
---|---|
中文名称 | 来那卡帕韦 |
CAS号 | 2189684-44-2 |
分子式 | C39H32ClF10N7O5S2 |
分子量 | 968.28 |
外观 | White to light yellow powder |
储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
英文名称 | Lenacapavir (Synonyms: GS-6207) |
---|---|
中文名称 | 来那卡帕韦 |
CAS号 | 2189684-44-2 |
分子式 | C39H32ClF10N7O5S2 |
分子量 | 968.28 |
外观 | White to light yellow powder |
储存条件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Lenacapavir (GS-6207) is a novel, first-in-class,long-acting and highly potent HIV-1 capsid inhibitor approved in EU on August 22, 2022 to treat HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis.